Literature DB >> 20165823

[Cutaneous leiomyomas. A key to the early recognition of malignant renal tumors?].

R Gläser1.   

Abstract

Entities:  

Mesh:

Year:  2010        PMID: 20165823     DOI: 10.1007/s00105-010-1926-7

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


× No keyword cloud information.
  5 in total

Review 1.  Uterine fibroids.

Authors:  E A Stewart
Journal:  Lancet       Date:  2001-01-27       Impact factor: 79.321

2.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.

Authors:  Ian P M Tomlinson; N Afrina Alam; Andrew J Rowan; Ella Barclay; Emma E M Jaeger; David Kelsell; Irene Leigh; Patricia Gorman; Hanan Lamlum; Shamima Rahman; Rebecca R Roylance; Simon Olpin; Stephen Bevan; Karen Barker; Nicholas Hearle; Richard S Houlston; Maija Kiuru; Rainer Lehtonen; Auli Karhu; Susa Vilkki; Päivi Laiho; Carita Eklund; Outi Vierimaa; Kristiina Aittomäki; Marja Hietala; Pertti Sistonen; Anders Paetau; Reijo Salovaara; Riitta Herva; Virpi Launonen; Lauri A Aaltonen
Journal:  Nat Genet       Date:  2002-02-25       Impact factor: 38.330

Review 3.  Clinical and molecular genetic aspects of hereditary multiple cutaneous leiomyomatosis.

Authors:  Sadhanna Badeloe; Jorge Frank
Journal:  Eur J Dermatol       Date:  2009-07-10       Impact factor: 3.328

4.  The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome.

Authors:  Maria J Merino; Carlos Torres-Cabala; Peter Pinto; William Marston Linehan
Journal:  Am J Surg Pathol       Date:  2007-10       Impact factor: 6.394

5.  Cutaneous leiomyomata with uterine leiomyomata.

Authors:  W B Reed; R Walker; R Horowitz
Journal:  Acta Derm Venereol       Date:  1973       Impact factor: 4.437

  5 in total
  1 in total

1.  [Hereditary metabolic diseases with cutaneous manifestations : An update].

Authors:  J Frank; P Poblete-Gutiérrez
Journal:  Hautarzt       Date:  2011-02       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.